Fosun International (00656) closed nearly 5% higher. The stock ended the day up 4.74% at HK$4.64, with turnover of HK$30.67 million.

On the news front, several listed companies under Fosun International recently released their earnings results. Fosun Pharma reported revenue of RMB 30.463 billion for the first three quarters, up 3.64% year-on-year; net profit attributable to shareholders was RMB 2.667 billion, up 5.71% year-on-year; and adjusted net profit attributable to shareholders (excluding non-recurring items) was RMB 1.706 billion, up 8.42% year-on-year.

In addition, Yuyuan Shares, another subsidiary of Fosun International, posted revenue of RMB 22.981 billion for the first three quarters, with net profit of RMB 168 million. Fosun High Tech reported net profit attributable to shareholders of RMB 505 million for the first three quarters, turning profitable year-on-year.

China Securities previously issued a research report stating that Fosun International's health segment, which includes listed companies such as Fosun Pharma, Henlius Biotech, and Sisram Medical, has achieved a tiered pipeline layout with a rich reserve of products under development. The happiness segment owns multiple high-quality assets and brands including Yuyuan Mall, Lao Miao Gold, Club Med, and Sanya Atlantis, continuously advancing global expansion. The wealth segment, which controls Fosun Portugal Insurance, Dingrui Reinsurance, HAL, and BFC, among others, continues to maintain steady expansion. Under the plan of "focusing on the core business and slimming down," the company will continue to advance its 8424 strategy in 2026.